Company Sector
CAR-T Therapy
CAR-T Therapy includes companies engineering chimeric antigen receptor T cells to recognize and kill target cells. This category remains central to hematologic malignancies and is also watched closely for attempts to expand cell therapy into autoimmune disease and solid tumors.
Why watch CAR-T Therapy
This page combines a company index, a watch action, and the newest relevant feed items in one place so readers can monitor a biotech theme without scanning each company one by one.
Latest CAR-T Therapy news
The latest feed items from companies currently grouped under CAR-T Therapy.
- 01
ALLOAllogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update
Source: Allogene Therapeutics
- 02
- 03
LEGNLegend Biotech to Host Investor Conference Call on Second Quarter 2026 Results
Source: Legend Biotech Corporation
- 04
LEGNLegend Biotech Announces CEO Transition
Source: Legend Biotech Corporation
- 05
- 06
LEGNLegend Biotech Corporation Announces Pricing of Public Offering
Source: Legend Biotech Corporation
- 07
LEGNLegend Biotech Corporation Announces Proposed Public Offering
Source: Legend Biotech Corporation
- 08
- 09
- 10
LEGNLegend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026
Source: Legend Biotech Corporation
- 11
ALLOAllogene Therapeutics Announces Planned CEO Succession
Source: Allogene Therapeutics
- 12
ALLOAllogene Therapeutics Announces Participation in Upcoming Investor Conferences
Source: Allogene Therapeutics
- 13
LEGNLegend Biotech Announces Presentations at ASCO 2026
Source: Legend Biotech Corporation
- 14
ALLOAllogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update
Source: Allogene Therapeutics
- 15
LEGNLegend Biotech Reports First Quarter 2026 Results and Recent Highlights
Source: Legend Biotech Corporation
- 16
ALLOAllogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
Source: Allogene Therapeutics
- 17
LEGNLegend Biotech Expands Scientific Advisory Expertise to Inform Future Growth
Source: Legend Biotech Corporation
- 18
LEGNLegend Biotech to Host Investor Conference Call on First Quarter 2026 Results
Source: Legend Biotech Corporation
- 19
ALLOAllogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia
Source: Allogene Therapeutics
- 20
Companies in CAR-T Therapy
6 companies tagged with CAR-T Therapy.
Frequently Asked Questions
What does the CAR-T Therapy sector include?
CAR-T Therapy includes companies engineering chimeric antigen receptor T cells to recognize and kill target cells. This category remains central to hematologic malignancies and is also watched closely for attempts to expand cell therapy into autoimmune disease and solid tumors.
How many companies are currently tagged with CAR-T Therapy?
6 companies are currently grouped under CAR-T Therapy on BioPharmSignal.
Which companies are most visible in the CAR-T Therapy group right now?
ALLO, CYAD, GILD, LEGN are among the companies currently shown on this sector page.
How can I watch news for CAR-T Therapy?
Use the Watch button on this page to subscribe to CAR-T Therapy headlines and related company updates through your BioPharmSignal saved filters.
What kinds of updates usually appear for CAR-T Therapy?
The livefeed typically surfaces company press releases, clinical readouts, FDA and regulatory updates, partnerships, financings, and commercialization developments tied to companies in CAR-T Therapy.